Arcus Biosciences
About Us
About Arcus
Leadership
Board of Directors
Scientific Advisory Board
Contact Us
Our Science
Pipeline
Clinical Candidates
Overview
Anti-TIGIT
domvanalimab
Adenosine Axis
etrumadenant
quemliclustat
Anti-PD-1
(zimberelimab)
HIF-2⍺ Inhibitor
(casdatifan)
Anti-CD39
(AB598)
AXL Inhibitor
(AB801)
Clinical Trials
Clinical Trials
Investigator Sponsored
Expanded Access Program
Publications
Editorials
Careers
Investors & Media
Overview
Press Releases
Events & Presentations
Events Calendar
Presentations
Stock Information
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Governance Documents
Management Team
Board of Directors
Committee Composition
Contact Investor Relations
Contact Investor Relations
FAQs
Email Alerts
Follow Us
X
LinkedIn
Sign Up for Updates
About Us
About Arcus
Leadership
Board of Directors
Scientific Advisory Board
Contact Us
Our Science
Pipeline
Clinical Candidates
Overview
Anti-TIGIT
domvanalimab
Adenosine Axis
etrumadenant
quemliclustat
Anti-PD-1
(zimberelimab)
HIF-2⍺ Inhibitor
(casdatifan)
Anti-CD39
(AB598)
AXL Inhibitor
(AB801)
Clinical Trials
Clinical Trials
Investigator Sponsored
Expanded Access Program
Publications
Editorials
Careers
Investors & Media
Overview
Press Releases
Events & Presentations
Events Calendar
Presentations
Stock Information
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Governance Documents
Management Team
Board of Directors
Committee Composition
Contact Investor Relations
Contact Investor Relations
FAQs
Email Alerts
Follow Us
X
LinkedIn
Sign Up for Updates
Sitemap
ABOUT US
ABOUT ARCUS
LEADERSHIP
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
CONTACT US
OUR SCIENCE
PIPELINE
CLINICAL CANDIDATES
Anti-TIGIT
domvanalimab
Adenosine Axis
etrumadenant
quemliclustat
Anti-PD-1
zimberelimab
HIF-2⍺ Inhibitor
Casdatifan
ANTI-CD39
AB598
AXL INHIBITOR
AB801
Clinical Trials
Investigator Sponsored
Expanded Access Program
Publications
EDITORIAL
CAREERS
INVESTORS
PRESS RELEASES
EVENTS & PRESENTATIONS
EVENTS CALENDAR
CORPORATE PRESENTATION
STOCK INFORMATION
ANALYST COVERAGE
STOCK INFORMATION
SEC FILINGS
CORPORATE GOVERNANCE
GOVERNANCE DOCUMENTS
MANAGEMENT TEAM
BOARD OF DIRECTORS
COMMITTEE COMPOSITION
CONTACT INVESTOR RELATIONS
CONTACT INVESTOR RELATIONS
FAQS
EMAIL ALERTS
FOLLOW US
X
LINKEDIN
SIGN UP FOR UPDATES